Skip to Content

Loteprednol / tobramycin ophthalmic Pregnancy and Breastfeeding Warnings

Loteprednol / tobramycin ophthalmic is also known as: Zylet

Loteprednol / tobramycin ophthalmic Pregnancy Warnings

Animal studies have revealed evidence of embryotoxicity (delayed ossification) and teratogenicity (increased incidence of meningocele, abnormal left common carotid artery, and limb fixtures) when loteprednol was administered orally at 35 times the maximum daily clinical dose. Reproductive studies in rats and rabbits with tobramycin at doses up to 100 mg/kg/day parenterally revealed no evidence of impaired fertility or fetal harm. There are no controlled data in human pregnancy. US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

Use only if the potential benefit justifies the potential risk to the fetus. US FDA pregnancy category: C

See references

Loteprednol / tobramycin ophthalmic Breastfeeding Warnings

Caution is recommended. Excreted into human milk: Unknown Excreted into animal milk: Data not available Comments: -Due to limited absorption from the eye, neither component is expected to cause any adverse effects in breastfed infants. -Placing pressure over the tear duct by the corner of the eye for at least 1 minute and removing excess solution with an absorbent tissue substantially reduces the amount of drug that reaches breast milk after using eye drops.

It is unknown whether topically administered ophthalmic corticosteroids could result in sufficient systemic absorption to produce detectable levels in breast milk; however, systemically administered corticosteroids may appear in breast milk and could suppress growth, interfere with endogenous corticosteroid production, or cause untoward effects.

See references

References for pregnancy information

  1. "Product Information. Zylet (loteprednol-tobramycin ophthalmic)." Bausch and Lomb, Rochester, NY.

References for breastfeeding information

  1. United States National Library of Medicine "Toxnet. Toxicology Data Network. Available from: URL: http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT." ([cited 2013 -]):
  2. "Product Information. Zylet (loteprednol-tobramycin ophthalmic)." Bausch and Lomb, Rochester, NY.

See Also...

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and Drugs.com is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide